94 35 NIH/NIAAA, Office of the Clinical Director 95 ABSTRACT 180
model, software used, effective N, number of SNPs and principal components are 291 presented for each sample in Supplementary Table S1 . 292
293
In addition to this primary analysis, subsets of genetically unrelated individuals were 294 selected from each family-based cohort (i.e. taking one individual per family) and used 295 to perform a conventional case/control GWAS using logistic regression. This was used 296 in place of the family-based GWAS for estimation of effect sizes and inclusion in 297 estimation of SNP-h 2 and genetic correlations (rg) using LD score regression analyses. 298
299 Meta-analysis: The primary discovery meta-analysis of all ancestry-stratified GWAS 300 (Ncase = 14,904; Ncontrol = 37,994) was conducted in METAL 28 . As the different study 301 designs (family vs. case-control) produced effect sizes that were not comparable, 302 results were combined using weighting by effective sample size (see Supplementary  303 Information). Separate ancestry-specific discovery meta-analyses of EU (N = 46,568) 304 and AA (N = 6,280) cohorts, respectively, were also performed. Heterogeneity was 305 evaluated across all cohorts and between study design subsets (Supplementary 306 Information). Power analysis was performed using CaTS 29 with the estimated effective 307 sample size. 308
309
In addition to the discovery meta-analyses, we conducted meta-analyses for two design 310 subsets. First, we performed sample size weighted meta-analysis of the subset of 311 genetically unrelated individuals in EU (N = 38,686) and AA (N = 5,799) cohorts for use 312 in LD score regression (LDSR) analysis. Second, we performed inverse-variance 313 weighted meta-analysis of genetically unrelated individuals in genotyped cohorts to 314 estimate within-ancestry effect sizes for EU (N = 28,757) and AA (N = 5,799). These 315 effect sizes were then used to compare trans-ancestral fine mapping results using 316 inverse-variance weighted fixed effects, random effects 30 , and Bayesian 31 models (Supplementary Information). Supplementary Table S2 provides an overview of the 318 various meta-analytic models that were fitted to data. 319 320 Heritability and Genetic Correlation Analysis: LDSR analysis 32 was performed to 321 estimate the heritability explained by common SNPs in meta-analyses of unrelated EU 322 and AA samples, respectively. LDSR was performed using HapMap3 SNPs and LD 323 scores computed from 1000 Genomes reference samples corresponding to each 324 population (Supplementary Information). Conversion of h 2 g estimates from observed to 325 liability scale was performed assuming population prevalences of 0.159 and 0.111 for 326 AD in alcohol-exposed EU and AA individuals, respectively 3 . 327 328 Genetic correlation between AD and 42 traits from LD Hub 33 and other published 329 studies [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] was examined with the same unrelated EU meta-analysis (10, 206 cases 330 and 28,480 controls) and precomputed European LD scores using LDSR. To avoid 331 increasing the multiple testing burden, redundant or highly-correlated phenotypes were 332 reduced by manually selecting the version of the phenotype with the greatest predicted 333 relevance to AD, largest sample size, or highest heritability (Supplementary 334 Information). 335 336 Replication: As described below, a locus on chromosome 3 was genome-wide 337 significant (GWS) in the trans-ancestral discovery meta-analysis. The minor allele, 338 associated with lower AD risk in our analysis, had low frequency in all EU samples 339 except the Finnish cohorts; it was also higher in AAs. To seek replication, we examined 340 the association between this locus and DSM-IV AD in two independent AA samples 341 (Yale-Penn 2, n = 911 cases and 599 controls, and COGA AAfGWAS, n = 880 cases 342 and 1,814 controls; Supplementary Information) using GEE (Yale-Penn) and Genome-343
Wide Association/Interaction Analysis and Rare Variant Analysis with Family Data 344 (GWAF; in COGA) respectively. Association with AD status, broadly defined using hospital and death records, was also examined in the FINRISK cohort (1,232 cases and 346 22,614 controls) using Firth logistic regression 45 . Figure S1 for QQ plot for discovery GWAS showing 353 polygenic signal). Examining individual populations, rs1229984 in ADH1B was the 354 strongest associated signal from the analysis in EU (p = 9.8E-13), while rs2066702, also 355 in ADH1B, was the most significant variant in AA (p = 2.2E-9; Figure 2 shows the 356 regional association plots for the ADH1B locus for the discovery, EU, AA and trans-357 ancestral meta-analysis). Clumping for linkage disequilibrium (LD; r 2 < .1 within 500kb) 358 suggested multiple independent signals within this locus in both populations ( Table 2) , 359 with differing leading alleles reflecting different LD structures and allele frequencies in 360 each population (Supplementary Figure S2A and S2B show LD patterns in the ADH 361 locus, including ADH1B, in AA and EU respectively). Conditional analysis controlling for 362 rs2066702 (Supplementary Figure S3 for results in AA) and rs1229984 (Supplementary 363 Figure S4 for results in EU) was inconclusive due to limited power, but was tentatively 364 consistent with the existence of additional independent effects in the region 365
( Supplementary Table S3 shows marginal and conditional effect sizes for genome-wide 366 significant SNPs in the ADH1B locus). The most promising support for an independent 367 signal arises from rs894368 (marginal odds ratio = 0.887, p = 6.9E-7; conditional odds 368 ratio = 0.890, p = 6.8E-6; Supplementary Information). Results from the trans-ancestral 369 meta-analysis reinforced the robust effects of rs1229984 and other ADH1B SNPs on 370 liability to AD (regional association plot for rs1229984 in Supplementary Figure S5A (inverse-variance weighted), S5B (modified random-effects) and S5C (Bayesian)) 372 across various analytic models.
We also verified whether variants affecting ADH1B expression (eQTLs) were associated 375 with AD. Considering GTEx data V7 (available at https://www.gtexportal.org/), 263 376 variants were reported to affect ADH1B expression in different human tissues (FDR 377 q<0.05). After LD-informed clumping and the exclusion of variants in LD with the GWS 378 coding alleles (i.e., rs1229984 and rs2066702), three variants (i.e., rs11939328, 379 rs10516440, rs7664780) were considered with respect to their association with AD. 380 SNP rs10516440 showed a genome-wide significant association with AD with 381 contribution from both AA and EU analyses (trans-ancestry p = 4.72E-8; EU p = 3.97E-382 6; AA p = 1.97E-3). In line with the effect of the coding variants where the protective 383 allele is associated with increased ADH1B enzymatic activity, the rs10516440*A allele 384 was associated with reduced AD risk and increased ADH1B expression, which was 385 consistent across multiple tissues (multi-tissue p = 1.42E-76). 386
387
A novel locus on chromosome 3, rs7644567, also achieved GWS in the meta-analysis 388 (p = 3.03E-8; Supplementary Figure S6 for regional association plot), primarily 389 attributable to contributions from the AA samples (p = 6.64E-6) with the major, A, allele 390 being associated with AD risk liability. The G allele has an MAF = 0.29 in AA, but 391 MAF<0.01 in most EU samples, except in FinnTwin (MAF = .032) and NAG-Fin (MAF = 392 0.054). In AA, rs7644567 does not appear to be in high LD with other variants 393 (Supplementary Figure S6 ) and did not replicate in two independent AA samples. In the 394 independent FINRISK cohort (MAF = .045), there was modest evidence for association 395 (p = 0.019), but with risk associated with the minor G allele ( Supplementary Table S4  396 for results in each replication sample). 397
398
Overall, there was limited evidence for heterogeneity across all cohorts, within ancestry, 399
between ancestries, or between study designs within ancestry (Supplementary 400 Information; Supplementary Figure S7 -S13). Gene-level association testing with MAGMA 46 did not identify any additional genes in EU or AA ( Supplementary Table S5  402 for top 20 genes in EU and AA). 403 404 Heritability and genetic correlations: LD score based liability-scale SNP-heritability of 405 AD was estimated at h 2 g = 0.090 (SE = 0.019, p = 8.02E-7) in the meta-analysis of 406 unrelated EU samples. Exclusion of the ADH1B locus did not substantially modify this 407 estimate (h 2 g = 0.089, SE = 0.0185). Nominally significant heritability from common 408 variants was also estimated for the meta-analysis of unrelated AA individuals based on 409 LDSR with scores computed from 1000 Genomes African populations (p = .017), but the 410 quantitative estimate of h 2 g was unstable depending on the choice of reference panel, 411 reflecting the challenge of correctly specifying LDSR and robustly modelling LD for the 412 admixed AA population (Supplementary Information). 413 414 Significant genetic correlation with AD in EU was observed for 16 traits (significant 415 genetic correlations in Figure 3 ; all genetic correlations in Supplementary Table S6) , 416 after correction for multiple testing (p = 1.19E-3 for 42 traits). The largest positive 417 correlations were with ever smoking tobacco (rg = .708, p = 1.3E-7) and lifetime 418 cannabis use (rg = .793, p = 2.5E-4), and with other psychiatric disorders and traits, 419 especially schizophrenia (rg = 0.357, p = 3.2E-11), ADHD (rg = .444, p = 4.2E-6), and 420 depressive symptoms (rg = .603, p = 2.6E-7). Educational attainment (rg = -0.424, p = 421 6.8E-9) and age at first birth (higher values indicate that subjects were older when they 422 had their first child, rg = -0.63, p = 2.0E-9) showed significant inverse genetic correlation 423
with AD suggesting that liability to AD risk was genetically related to lower educational 424 attainment and lower age at which one had their first child. 425
426
Unexpected patterns of genetic correlation were observed when comparisons were 427 made to other alcohol-related measures. AD was genetically correlated with alcohol 428 consumption in a meta-analysis of the Alcohol Genome-wide Association (AlcGen) and
Cohorts for Aging and Research in Genomic Epidemiology Plus (CHARGE+) 430 consortia 36 (rg = .695, p = 6.9E-6) but only modestly with alcohol consumption from the 431 recent large UK Biobank analysis 37 (rg = 0.371, p = 5.2E-5). Liability to AD was not 432 correlated with genome-wide SNPs from a recent GWAS of the Alcohol Use Disorders 433
Identification Test (AUDIT) in 23andMe 38 (rg = 0.076, p = 0.65), perhaps due to the low 434 levels of drinking observed in this population 38 . Additional analysis indicates AD is 435 genetically correlated with GWAS of delay discounting in the 23andMe sample 42 (rg = 436 0.478, p = 6.0E-3), suggesting behavioral phenotypes in the cohort are still informative 437 to AD. 438
439
Associations with other GWS loci: We examined results for the eight independent 440 variants associated at GWS levels with alcohol consumption in the UK Biobank 37 441
( Supplementary Table S7 ). Among the UK Biobank findings, three of the four reported 442 variants in the ADH region of chromosome 4 (rs145452708 -a proxy for rs1229984, 443 rs29001570 and rs35081954) were associated in the present study with AD (p ranging 444 from 3.5E-5 -2.3E-10) with sign concordant effects; the remaining variant was 445 excluded from our analysis due to MAF <0.01. The UK Biobank lead variant in KLB, 446 rs11940694, was nominally associated with AD (p = .0097), though this does not 447 surpass multiple testing correction for the eight GWS alcohol consumption loci. We see 448 little evidence (p >0.2) for association of AD with the reported loci at GCKR and 449 CADM2, which may be due to differences in power for the given effect size or because 450 these genes exert an influence on liability to consume alcohol but not later problems. 451
The locus on chromosome 18 showed limited regional association with AD, but the 452 index variant was not present in our analysis because it no longer appears in the 1000 453
Genomes Phase 3 reference panel 25 . 454 455 Power analysis: Only 3 additional loci reach p < 1E-6 ( Table 2) . Power analyses 456 indicated that the current meta-analysis is expected to have at least 63% power to 457 detect very common variants (MAF ≥ 0.25) with odds ratios ≥ 1.10 at p < 1E-6 (41% for p < 5E-8; Supplementary Figure S14 for power analysis curves). Power is lower for 459 less common variants (MAF ≥ .05) even with odds ratios ≥ 1.20 at p < 1E-6 (60% power) 460 and p < 5E-8 (38% power). To our knowledge, this is the largest GWAS of rigorously-defined AD. We identified loci 465 in ADH1B that differed between EU and AA, as well as novel genetic correlations 466 between AD and psychiatric disorders (e.g., schizophrenia), tobacco and cannabis use, 467 and behavioral outcomes (e.g., educational attainment). Analyses also revealed a 468 genetic distinction between GWAS results for alcohol consumption and AD. Although 469 larger sample sizes can be amassed by focusing on quantitative measures of 470 consumption, only the upper tail is relevant to AD (as a medical diagnosis) and even 471 that does not capture other aspects of disordered drinking (e.g., loss of control, 472 withdrawal) directly. Conversely, cases derived from electronic medical records (e.g., 473
ICD codes) may result in a high rate of false negatives, while self-screening instruments 474 (e.g. AUDIT scores) is best suited to analyses of disordered drinking when a sufficiently 475 high threshold or score cut-off is applied to pinpoint severity. Our study has the 476 advantage of greater diagnostic precision via use of semi-structured interviews to 477 diagnose AD systematically in a majority of the constituent studies. 478
479
The genome-wide significant SNPs reaffirm the importance of functional variants 480 affecting alcohol metabolism to the risk of AD. The top association in ADH1B, 481 rs1229984, is a missense variant that is amongst the most widely studied in relation to 482 alcohol use, misuse and dependence. The resulting amino acid substitution (Arg48His) 483 increases the rate at which ADH1B oxidizes ethanol to acetaldehyde 10, 11 . Early studies 484 on Asian populations in which the derived allele is common demonstrated strong 485 protection against the development of AD [9] [10] [11] . In EUs and AAs, the protective allele is present at much lower frequencies (EU MAF = 3-4%, AA MAF < 1%), but recent large-487 scale studies have shown an association between this locus and alcohol consumption 488 and problems at GWS levels in EU with similar effect size 14, 15 . The lead variant in AA 489 cohorts, rs2066702 (Arg370Cys), is another functional missense variant in ADH1B, and 490 it, similarly, encodes an enzyme with an increased rate of ethanol oxidation 10, 11 . The 491 allele encoding Cys370 is common among AAs, but rare in other populations 10 . Our 492 results clearly show that these two different functional SNPs in ADH1B both affect risk 493 for alcoholism, with their relative importance dependent upon allele frequency in the 494 population studied. Larger future studies will be needed to evaluate the evidence for 495 additional independent effects in the chromosome 4 locus. 496
497
The only other locus to reach significance was rs7644567 on chromosome 3, primarily 498 driven by AA cohorts due to the variant's very low MAF in EU. This locus did not 499 replicate in independent African or Finnish ancestry samples. We note that the 500 conventional genome-wide significance threshold is derived for European ancestry 501 samples, and thus is likely to be too lenient in GWAS of African-ancestry cohorts due to 502 higher genetic diversity and corresponding increase in the effective number of 503 independent tests in the GWAS 47, 48 . As an illustration, in 4 samples from the current 504 study that included both EU and AA participants, the number of independent SNPs 505 identified upon LD pruning was 1.7-to 2.3-fold greater in AA than EU subjects. Much 506 larger studies in AA and other non-EU populations will clearly be important to elucidate 507 additional loci. 508
509
Despite limited SNP-level findings, there is significant evidence for polygenic effects of 510 common variants in both EU and AA cohorts. The estimated h 2 g = .09 for AD in EU is 511 only modestly lower than those recently reported for alcohol consumption (h 2 g = .13) 37 512 and AUDIT scores (h 2 g = .12) 38 , and comparable to estimates derived for cigarettes-per-513 day 33 . Our h 2 g estimate is lower than a prior report 8 , likely reflecting a combination of 514 differences in estimation method and greater heterogeneity in ascertainment strategy across samples in the current study. The latter is especially relevant given that we 516 incorporated population-based cohorts with a wide range of ages at ascertainment and 517 cultural environments, as well as cohorts enriched for other substance use disorders. 518
519
Comparing our GWAS to recent GWAS of alcohol consumption measures suggests that 520 the liability underlying normative patterns of alcohol intake and AD are only partially 521 overlapping. Genome-wide, we observe only modest genetic correlation (significantly < 522 1) with log-scaled alcohol consumption by participants in AlcGen and CHARGE+ 523
Consortia cohorts 36 (rg = .695) and in the UK Biobank 37 (rg = .371), and no significant 524 correlation with GWAS of log-scaled AUDIT scores in 23andMe participants 38 
.076). We also observe only partial replication of the 8 loci significantly associated with 526 consumption in the UK Biobank. One key factor in interpreting the differences between 527 these traits and AD is that the distribution of consumption levels and AUDIT scores can 528 be highly skewed in population samples, with most individuals at the low 529 (nonpathological) end of the spectrum. This effect may be especially pronounced 530 among the older, healthy volunteers of the UK Biobank cohort 49 and the 23andMe 531 cohort, which is more educated and has higher socioeconomic status than the general 532 US population 38 . We hypothesize that the variants that affect consumption at lower 533 levels may differ substantively from those that affect very high levels of consumption in 534 alcohol dependent individuals, who are also characterized by loss of control over 535 intake 50 . This appears to be the case in one prior study that used specific cut-offs to 536 harmonize AUDIT scores with AD data and noted significant concordance in SNP-h 2 537 estimates 51 -according to that study, the optimal cutoffs for their sample were ≥6 and 538 ≥9 for women and men respectively. However, there is a need for a further detailed 539 characterization of how AUDIT cut-offs may be applied to maximize concordance with 540 genetic liability to AD diagnosis risk. The strongly negative genetic correlation between 541 educational attainment and AD, in contrast to positive genetic correlations of education 542 with consumption and AUDIT scores, further underscore this distinction between normative/habitual levels of alcohol intake and diagnosed AD, at least in the respective 544 populations studied. 545
546
The current analysis also identified robust genetic correlation of AD with a broad variety 547 of psychiatric outcomes. This correlation is strongest for aspects of negative mood, 548
including neuroticism and major depressive disorder, as also seen in twin studies 52,53 549 and through recent specific molecular evidence for pleiotropy 54, 55 . Taken together with 550 evidence from other recent genomic studies 54 , and null correlations for other GWAS of 551 alcohol consumption, these findings suggest that major depression may only share 552 genetic liability with alcohol use at pathological levels. 553 554 AD was also negatively genetically correlated with AFB, which is an indicator of 555 reproductive tempo and correlated with age at first consensual sexual intercourse 56 . 556 This is consistent with evidence of common genetic liability to early, risky behaviors 557 underlying AD and AFB 57 . Nominally significant genetic correlation with delay 558 discounting (i.e. favoring immediate rewards) and the strong genetic correlation of AD 559 with ADHD, cigarette smoking and cannabis use may similarly reflect a shared genetic 560 factor for risk-taking and reduced impulse control. 561 562 Lower genetic correlations were observed for most biomedical and anthropometric 563 outcomes. Liver enzymes GGT and ALT, once proposed as possible biomarkers for 564 alcohol abuse 58 , showed, as expected, nominal evidence for genetic correlation with AD 565 but neither survived multiple testing correction. Notably, we did not find any association 566 between AD and body-mass index (BMI). Negative genetic correlations with BMI were 567 previously reported for both alcohol consumption 37 and AUDIT scores 38 , but there is 568 prior evidence that BMI has differing underlying genetic architecture in the context of AD 569 and outside of that context 59 . The negative genetic correlations observed in those 570 studies are consistent with studies of light to moderate drinking, which is also associated with healthier lifestyle behaviors, while heavy and problematic drinking is 572 typically associated with weight gain 60 . 573
574
This study benefits from precision in diagnostic assessment of AD, known alcohol 575 exposure in a majority of the controls, and careful quality control that excluded overlaps 576 of individuals between studies while combining case-control and twin/family-based 577 study designs. Despite these strengths our sample size was insufficient to identify 578 additional GWS loci robustly. Power analyses indicate that additional SNPs associated 579 with AD are likely to have small effect sizes, consistent with other psychiatric disorders 580 (e.g. depression 61 ). This supports the pressing need for collection of large numbers of 581 well characterized cases and controls. The differences between our results and the 582 study of AUDIT scores 38 , however, highlight that ascertainment and trait definition must 583 also be taken into account. Careful study of how screening tools, such as the AUDIT, 584 correlate to genetic liability to AD (as defined by DSM-IV or similar) could substantially 585 boost sample sizes for future AD GWAS. There is also a continued need to characterize 586 the genetic architecture of AD in non-EU populations. 587
588
We show a novel genetic distinction between drinking in the pathological range (AD) 589 and habitual drinking that does not cross the threshold into pathology or dependence. 590
Larger future samples will allow us to uncover additional pleiotropy between 591 pathological and non-pathological alcohol use as well as between AD and other 592 neuropsychiatric disorders. Overview of numbers of alcohol dependent cases and controls from each cohort in the current analysis, including the number of genetically unrelated individuals. Cohorts are listed by study design. Sample sizes are listed after QC exclusions and stratified by ancestry group. PubMed identifiers (PMID) are listed for previous publications describing each cohort, along with the percentage of male samples and the age range in the cohort. Top 10 nominally independent variants from the discovery trans-ancestral (Trans.) meta-analysis and the discovery metaanalyses in African (AA) and European (EU) ancestry cohorts, respectively. Independent variants are identified based on clumping for LD (pairwise r 2 < 0.1) in 1000 Genomes Project Phase 3 data 25 . EU results are clumped using European 
